医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ReproCELL Launches New Culture Medium for High Quality Human Naïve iPS Cells, “ReproNaïveTM”

2015年06月22日 PM09:30
このエントリーをはてなブックマークに追加


 

YOKOHAMA, Japan

ReproCELL (JASDAQ:4978) is pleased to announce that we will start selling new culture medium for high quality human iPS (naïve type) for the first time in the world, “ReproNaïveTM”, into which the most advanced iPS cell technology is introduced.

Since Professor Shinya Yamanaka of Kyoto University pioneered iPS technology in 2006, iPS has been researched and developed all over the world as an innovative technology for regenerative medicine. Meanwhile, researchers of Massachusetts Institute of Technology discovered higher quality and more ideal iPS cells (naïve type) in May 2010. Human naïve iPS cells are reprogrammed in an ideal state closer to a fertilized egg than human iPS cells of conventional technology; they have remarkable capabilities such as the proliferation ability of 100 times as extremely high as conventional human iPS cells (compared by culturing for 10 days), and it is also easy to steadily maintain cultured cells undifferentiated. The high proliferation ability and the ease of handing due to the quality stability command considerable attention in the world of iPS technology from the reason of usefulness in industries.

Great expectations have been placed on human naïve iPS cells, however, it was technologically highly demanding, for example, the reproducibility was limited to some research groups. We have solved these technical issues to successfully commercialize the all-in-one product for the first time in the world, ReproNaïveTM, which enables anyone to easily produce human naïve iPS cells. Normal human iPS cells transform to the naïve type by culturing them in ReproNaïveTM, which realizes high proliferation ability of 100 times conventional human iPS cells (cultured for 10 days) and high quality stability. ReproNaïveTM is able to multilaterally and dramatically improve the industrial value of iPS cells, and holds promise to significantly accelerate the regenerative medicine that iPS cell technologies are applied to.

We will endeavor to develop the world’s most advanced products, play a leading role in the market, and pioneer the future of medicine including regenerative medicine.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150622005544/en/

CONTACT

ReproCELL, Inc.
Chikafumi Yokoyama, +81-45-475-3887
PhD
info_en@reprocell.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • PotNetwork Holdings, Inc.在注册成为SEC报告公司之后发布PCAOB经审计和审核的完整财务报表
  • PotNetwork Holdings, Inc.提交Form 10以成为美国证券交易委员会报告公司
  • レスメド初の最小接触面フルフェイスCPAPマスクAirFit F30を米国とカナダで販売開始
  • Foundation Medicine Announces Strategic Collaboration with Major Pharmaceutical Company
  • Biogen and Samsung Bioepis Announce European Launch of IMRALDI™(adalimumab), Solidifying Leadership in European Anti-TNF Market